{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:48:21Z","timestamp":1788536901040,"version":"build-2803163510"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.clml.2021.09.011","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T14:20:22Z","timestamp":1632147622000},"page":"140-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Refractory DLBCL: Challenges and Treatment"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4347-173X","authenticated-orcid":false,"given":"Mendel","family":"Goldfinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0233-8876","authenticated-orcid":false,"given":"Dennis L.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.09.011_bib0001","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.09.011_bib0002","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large b-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0003","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","article-title":"Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-Cell lymphoma","volume":"35","author":"Leonard","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0004","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0005","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01375","article-title":"Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0006","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-Cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0007","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.clml.2021.09.011_bib0008","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2021.09.011_bib0009","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.clml.2021.09.011_bib0010","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-Cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.09.011_bib0011","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2021.09.011_bib0012","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1200\/JCO.2017.72.2157","article-title":"Outcomes of patients with double-hit lymphoma who achieve first complete remission","volume":"35","author":"Landsburg","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0013","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ajh.26068","article-title":"First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study","volume":"96","author":"Laude","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.09.011_bib0014","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.19.00743","article-title":"Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the lunenburg lymphoma biomarker consortium","volume":"37","author":"Rosenwald","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0015","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0016","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1158\/1078-0432.CCR-19-3741","article-title":"A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma (DLBCL) with poor prognosis features","volume":"26","author":"Sarkozy","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2021.09.011_bib0017","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2021.09.011_bib0018","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMc1609333","article-title":"Interim PET-CT Scan in Advanced Hodgkin's Lymphoma","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.09.011_bib0019","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.20.00999","article-title":"Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of intergroup national clinical trials network study S1001","volume":"38","author":"Persky","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0020","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron emission tomography-guided therapy of aggressive non-hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial","volume":"36","author":"Duhrsen","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0021","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/bloodadvances.2021004467","article-title":"Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients","volume":"5","author":"Eertink","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.09.011_bib0022","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1200\/JCO.2018.78.9362","article-title":"Response-adapted therapy in aggressive lymphoma: not yet ready for clinical care","volume":"36","author":"Merryman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Supplment 1","key":"10.1016\/j.clml.2021.09.011_bib0023","first-page":"405","article-title":"Interim analysis of ZUMA-12: A Phase 2 study of Axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients with high risk large B cell lymphoma","volume":"136","author":"Neelapu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.011_bib0024","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JOP.19.00691","article-title":"Potential of circulating tumor DNA for the management of patients with lymphoma","volume":"16","author":"Huet","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clml.2021.09.011_bib0025","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating Tumor DNA measurements as early outcome predictors in diffuse large B-Cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0026","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/hematology.2019000013","article-title":"Prognostication with circulating tumor DNA: is it ready for prime time?","volume":"2019","author":"Kurtz","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2021.09.011_bib0027","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.011_bib0028","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.09.011_bib0029","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.09.011_bib0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.09.011_bib0031","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1200\/EDBK_279043","article-title":"ADCs, BiTEs, CARs, and small molecules: a new era of targeted therapy in non-hodgkin lymphoma","volume":"40","author":"Abramson","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clml.2021.09.011_bib0032","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S2666-6367(21)00096-8","article-title":"Prophylactic steroid use with axicabtagene ciloleucel in patients with relapsed\/refractory large B cell lymphoma (abstract)","volume":"27","author":"Oluwole","year":"2021","journal-title":"Transplantation and Cellular Therapy"},{"key":"10.1016\/j.clml.2021.09.011_bib0033","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2019.243246","article-title":"Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed\/refractory large B-cell lymphoma","volume":"106","author":"Lin","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.09.011_bib0034","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D'Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.09.011_bib0035","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1182\/blood.2020007939","article-title":"Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?","volume":"137","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.011_bib0036","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0037","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.011_bib0038","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/bloodadvances.2019000593","article-title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","volume":"3","author":"Shadman","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.09.011_bib0039","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.bbmt.2019.12.771","article-title":"Cellular immunotherapy for refractory diffuse large B cell lymphoma in the chimeric antigen receptor-engineered T cell era: still a role for allogeneic transplantation?","volume":"26","author":"Dreger","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.09.011_bib0040","first-page":"1832","article-title":"Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy","volume":"137","author":"Spiegel","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.011_bib0041","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.09.011_bib0042","article-title":"CD22-Directed CAR T-cell therapy induces complete remissions in CD19-directed car-refractory large B-cell lymphoma","author":"Baird","year":"2020","journal-title":"blood"},{"key":"10.1016\/j.clml.2021.09.011_bib0043","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.clml.2021.09.011_bib0044","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0045","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.09.011_bib0046","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.011_bib0047","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.09.011_bib0048","first-page":"1","article-title":"Generation of a half-life extended anti-CD19 BiTE antibody construct compatible with once-weekly dosing for treatment of CD19-positive malignancies","volume":"130","author":"Lorenczewski","year":"2017","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2021.09.011_bib0049","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.011_bib0050","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.09.011_bib0051","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.09.011_bib0052","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.011_bib0053","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2021.09.011_bib0054","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood-2020-136539","article-title":"Polatuzumab vedotin in relapsed and refractory large B-cell lymphoma (LBCL): Real-World data of the German national compassionate use program (CUP)","volume":"136","author":"Liebers","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.011_bib0055","article-title":"Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma","author":"Hamadani","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.011_bib0056","series-title":"ASH annual Meeting 2020 December 6","article-title":"2099 Interim Results of Loncastuximab Tesirine Combined with Ibrutinib in Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)","author":"NDW-J","year":"2020"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2021.09.011_bib0057","first-page":"121","article-title":"VLS-101, a ROR1-targeting antibody-drug conjugate, demonstrates a predictable safety profile and clinical effiacy in patient with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.011_bib0058","article-title":"Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA","author":"Le Gouill","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.011_bib0059","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0060","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1111\/bjh.16302","article-title":"Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma","volume":"188","author":"Rodgers","year":"2020","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2021.09.011_bib0061","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1182\/blood-2020-139260","article-title":"Pre-CAR blinatumomab is associated with increased post-CD19 CAR relapse and decreased event free survival","volume":"136","author":"Taraseviciute","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.011_bib0062","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1200\/JCO.20.01522","article-title":"Checkpoint blockade in lymphoma","volume":"39","author":"Ansell","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0063","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse Large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0064","series-title":"Relapsed\/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis. ASH annual Meeting","article-title":"Phase 1b\/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide)","author":"Melani","year":"2020"},{"key":"10.1016\/j.clml.2021.09.011_bib0065","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/JCO.2019.37.15_suppl.7508","article-title":"Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma","volume":"37","author":"Westin","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0066","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.09.011_bib0067","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2021.09.011_bib0068","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood-2020-136659","article-title":"Blood (Supplement 1) Odronextamab (REGN1979), a human CD20 X CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B cell Non-Hodgkin lymphoma, including patients refractory to CAR T therapy","volume":"136","author":"Bannerji","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.011_bib0069","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting t-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2021.09.011_bib0070","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood-2020-133820","article-title":"Subcutaneous epcoritamab induced complete responses with an encouraging safety profile across relapsed\/refractory B-cell Non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: updated dose escalation data","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.011_bib0071","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2021.09.011_bib0072","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase i first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0073","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0074","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/annonc\/mdn031","article-title":"Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma","volume":"19","author":"Crump","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.09.011_bib0075","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.2018891598","article-title":"Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed\/refractory non-germinal center B-cell-like DLBCL","volume":"134","author":"Goy","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.011_bib0076","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00277-021-04535-7","article-title":"Ibrutinib combined with venetoclax for the treatment of relapsed\/refractory diffuse large B cell lymphoma","volume":"100","author":"Zhou","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.09.011_bib0077","first-page":"759","article-title":"Preliminary results from a phase I trial of pembrolizumab plus vorinostat in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and hodgkin lymphoma","volume":"134","author":"LC","year":"2019","journal-title":"ASH annual Meeting"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021020413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021020413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:04Z","timestamp":1761871084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021020413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2152265021020413"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.09.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refractory DLBCL: Challenges and Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}